NCT00963417 2025-07-14
TEXT-Bone
ETOP IBCSG Partners Foundation
Phase NA Completed
Clinical Trials
8 trialsNCT00688246 2023-08-04
Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3
Canadian Cancer Trials Group
Completed
NCT00354302 2020-04-02
Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial
Canadian Cancer Trials Group
Phase 3 Completed
NCT00305695 2020-03-24
Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
GOG Foundation
Phase 2 Completed
NCT00329797 2017-11-29
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00324714 2012-11-29
Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS
ETOP IBCSG Partners Foundation
Phase 3 Withdrawn
NCT00369850 2012-07-27
Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT00228124 2006-01-26
PR.7 Companion Trial: Effect of Intermittent Versus Continuous Androgen Suppression on Bone Loss and Body Composition
Ontario Cancer Research Network
Unknown